Oncology Conference update  

ASCO 2024 lung cancer highlights

A conference update on lung cancer clinical trial data from ASCO

Prof. Mark Socinski

Prof. Mark Socinski
Publication Date

Jun 2024

info Summary and next episodes

Professor Mark Socinski joins us live from ASCO 2024 to share his views on the lung cancer data emerging from the conference.

 

In this short video update, he shares his insights on data from the LAURA and ADRIATIC trials and what they could mean for clinical practice in lung cancer management.

 

ASCO 2024 selected lung cancer abstracts

  • Osimertinib after definitive chemoradiotherapy in patients with unresectable stage 3 EGFRm NSCLC: Primary results of the phase 3 LAURA study.
    Ramalingam S, et al.
    Abstract LBA4, ASCO 2024

 

  • ADRIATIC: durvalumab as consolidation treatment for patients with limited-stage small-cell lung cancer.
    Spigel D, et al.
    Abstract LBA5, ASCO 2024

 

Prof. Mark Socinski is a Medical Oncologist and Executive Medical Director of the AdventHealth Cancer Institute, Orlando, Florida. Specialises in all thoracic malignancies, including small cell and non-small cell lung cancers and mesothelioma. An internationally recognised expert in the development of novel chemotherapy agents and treatment strategies for advanced non-small cell lung cancer and small cell lung cancer. Research has focused on incorporating personalised medicine and molecular biomarkers in the treatment of lung cancer. Formerly Co-Chair of the Thoracic Malignancies Steering Committee for the National Cancer Institute and served on the Respiratory Core Committee of the Cancer and Leukemia Group B (Alliance). Tenured Professor at the University of North Carolina and the University of Pittsburgh.

Prof. Mark Socinski has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Beigene, BMS, Cullinan, Eli Lilly, Genentech, GI Therapeutics, Guardant, Janssen, Jazz, Merck, Novartis, OncoC4, Regeneron, Spectrum, Summit
Programme summary
  • clock Duration 4 MIN
  • clock Language(s) flag
Watch the video now
Other episodes of this series
ASCO 2024 lung cancer highlights

ASCO 2024 lung cancer highlights

A conference update on lung cancer clinical trial data from ASCO

 Current Episode
ASCO 2024 breast cancer highlights

ASCO 2024 breast cancer highlights

How could the data impact clinical practice?
ASCO 2024 HCC highlights

ASCO 2024 HCC highlights

How could the latest clinical trial data impact the management of hepatocellular carcinoma?
ASCO 2024 upper GI cancer highlights

ASCO 2024 upper GI cancer highlights

Practice-changing upper GI trial data direct from ASCO 2024
Share this programme
x-twitter
Supporter Acknowledgement
I agree that this educational programme:

Was valuable to me

1/4

Other programmes of interest

conference-update Conference update
Oncology 
Update from AACR–NCI–EORTC 2025: PYNNACLE Phase 2 evaluating rezatapopt in TP53 Y220C–mutant solid tumours

Clinical insights and expert discussion

Experts
Dr Alison Schram, Dr Elena Garralda
  • download Downloadable
    Resources
  • clock MIN
  • calendar Oct 2025
COR2ED
This programme has been sponsored by PMV Pharma 
conference-update Conference update
Oncology 
Highlights from ESMO 2025

Experts join us at ESMO 2025 to share their views on new data on GU, lung, breast, gynecological and upper GI cancers

Experts
Dr Herbert Loong, Prof. Viktor Grünwald, Prof. Thomas Powles, Dr Elisa Agostinetto, Prof. Nicoletta Colombo, Dr Elizabeth Smyth
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
  • download Downloadable
    Resources
  • clock MIN
  • calendar Oct 2025
  • Non-accredited Independent Medical Education
COR2ED GU NURSES CONNECT PRECISION ONCOLOGY CONNECT GI NURSES CONNECT OBSTETRICS & GYNECOLOGY CONNECT 
NSCLC and RCC updates supported by Independent Education Grants from Bayer and Eisai Europe Ltd. respectively. All other updates supported by COR2ED.
podcast Video podcast
Oncology Endocrinology Rare diseases 
Exploring the role of targeted radiopharmaceutical treatment in NETs

PRRT and emerging strategies in neuroendocrine tumours

Experts
Prof. Ken Herrmann, Dr Heloisa Soares, Oncology Brothers (Moderators)
Endorsed by
NANETS
CommNETs Neuroendocrine Cancer UK
  • download Downloadable
    Resources
  • clock 21 MIN
  • calendar Oct 2025
  • Non-accredited Independent Medical Education
NET CONNECT GI CONNECT
Educational programme supported by an Independent Educational Grant from ITM.
ipcv Interactive Patient Case Video (IPCV)
Oncology 
Shared decision-making for prostate cancer patients

Early treatment intensification with a PARPi plus ARPI combination

Experts
Prof. Gunhild von Amsberg
Endorsed by
ZERO Urobel VZW | ASBL
EAUN
  • clock 25 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education
GU CONNECT GU NURSES CONNECT PRECISION ONCOLOGY CONNECT
Educational programme supported by an Independent Educational Grant from AstraZeneca 
conference-update Conference update
Oncology 
Oncogene-addicted NSCLC highlights from WCLC 2025

Expert insights on the latest data in oncogene-addicted non-small cell lung cancer 

Experts
Dr Devika Das
Endorsed by
Exon20group Biomarker Collaborative ICAN international cancer advocacy network
Lung Cancer Europe
Lung Cancer Research Foundation
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education
LUNG CONNECT PRECISION ONCOLOGY CONNECT
Educational programme supported by an Independent Educational Grant from Bayer.
podcast Video podcast
Oncology 
Understanding the BRAFV600E testing and treatment landscapes in NSCLC

Two perspectives, one aim: A pathologist and a medical oncologist in discussion

Experts
Assoc. Prof. Umberto Malapelle, Prof. Nicolas Girard
Endorsed by
ISLB
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2025
  • Non-accredited Independent Medical Education
LUNG CONNECT PRECISION ONCOLOGY CONNECT
This content is intended for HCPs outside the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This programme is supported by an Independent Educational Grant from Pierre Fabre Laboratories.  The programme is, therefore, independent; the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. 
Explore all programmes